HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

[The clinical efficacy of Naftopidil tablet in the treatment of benign prostatic hyperplasia].

AbstractOBJECTIVES:
To evaluate the clinical efficacy and safety of Naftopidil tablet in treating benign prostatic hyperplasia.
METHODS:
Eighty BPH patients were divided into two groups randomly by double-blind, double-simulated and active control parallel study trials. Forty patients in treatment group were given Naftopidil tablet 25 mg, p.o., qn for 42 days, while 40 patients in control group were given Tamsulosin 0.2 mg, p.o., qn for 42 days. Statistical analysis was given from 77 cases in the groups. Estimation of the efficacy was done by the change of major indexes include international prostate symptom score (IPSS), maximum flowrate (Qmax) and secondary indexes such as quality of life (QOL), residual urine (Ru) and volume of prostate (V).
RESULTS:
The changes of IPSS, Qmax, QOL had significant difference between two groups before and after treatment(P < 0.05). The change of Ru had no significant difference between two groups before and after treatment (P > 0.05) while there was significant difference between two groups after six-week treatment(P < 0.05). The change of V had no significant difference (P > 0.05). The adverse reactions in both groups were mild, and there was no significant difference between two groups(P > 0.05).
CONCLUSIONS:
Naftopidil tablet was safe and effective in treating benign prostatic hyperplasia.
AuthorsXiao-Bing Ju, Hong-Fei Wu, Jian-Tang Su
JournalZhonghua nan ke xue = National journal of andrology (Zhonghua Nan Ke Xue) Vol. 8 Issue 4 Pg. 286-8 ( 2002) ISSN: 1009-3591 [Print] China
PMID12491697 (Publication Type: Clinical Trial, English Abstract, Journal Article, Randomized Controlled Trial)
Chemical References
  • Adrenergic alpha-1 Receptor Antagonists
  • Adrenergic alpha-Antagonists
  • Naphthalenes
  • Piperazines
  • Tablets
  • naftopidil
Topics
  • Adrenergic alpha-1 Receptor Antagonists
  • Adrenergic alpha-Antagonists (therapeutic use)
  • Aged
  • Double-Blind Method
  • Humans
  • Male
  • Middle Aged
  • Naphthalenes (adverse effects, therapeutic use)
  • Piperazines (adverse effects, therapeutic use)
  • Prostatic Hyperplasia (drug therapy, psychology)
  • Quality of Life
  • Tablets

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: